Technical Analysis for ASMB - Assembly Biosciences, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical ASMB trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Calm After Storm | Range Contraction | 1.71% | |
| Calm After Storm | Range Contraction | 0.89% | |
| NR7 | Range Contraction | 0.89% | |
| Inside Day | Range Contraction | 0.89% | |
| 20 DMA Resistance | Bearish | -2.42% | |
| Spinning Top | Other | -2.42% | |
| Calm After Storm | Range Contraction | -2.42% | |
| Fell Below 20 DMA | Bearish | -0.79% | |
| Fell Below 50 DMA | Bearish | -0.79% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
Assembly Biosciences, Inc. provides development and commercialization of gastrointestinal products in the United States. The company is developing two late-stage development product candidates, including VEN 307, a diltiazem cream for the relief of pain associated with anal fissures; and VEN 308, a phenylephrine gel for the treatment of fecal incontinence associated with ileal pouch anal anastomosis. It is also involved in the development of VEN 310 as a colonic delivery mechanism, which is a PH sensitive system to deliver bacteria, complex proteins, viral antigens, small molecules, and other treatments. The company was formerly known as Ventrus Biosciences Inc. and changed its name to Assembly Biosciences, Inc. in July, 2014. Assembly Biosciences, Inc. was founded in 2005 and is based in New York, New York.
Medicine Medical Specialties Gastroenterology Digestive System Digestive System Surgery Large Intestine Fecal Incontinence Gastrointestinal Products
Medicine Medical Specialties Gastroenterology Digestive System Digestive System Surgery Large Intestine Fecal Incontinence Gastrointestinal Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ASMB news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 41.0 |
| 52 Week Low | 11.49 |
| Average Volume | 299,477 |
| 200-Day Moving Average | 18.5762 |
| 50-Day Moving Average | 13.482 |
| 20-Day Moving Average | 12.706 |
| 10-Day Moving Average | 12.851 |
| Average True Range | 0.8086 |
| ADX | 17.87 |
| +DI | 20.4376 |
| -DI | 23.4044 |
| Chandelier Exit (Long, 3 ATRs ) | 12.1442 |
| Chandelier Exit (Short, 3 ATRs ) | 13.9158 |
| Upper Bollinger Band | 14.0744 |
| Lower Bollinger Band | 11.3376 |
| Percent B (%b) | 0.42 |
| BandWidth | 21.53943 |
| MACD Line | -0.2407 |
| MACD Signal Line | -0.2568 |
| MACD Histogram | 0.0161 |
| Fundamentals | Value |
|---|---|
| Market Cap | 216.87 Million |
| Num Shares | 17.4 Million |
| EPS | -2.93 |
| Price-to-Earnings (P/E) Ratio | -4.26 |
| Price-to-Sales | 176.68 |
| Price-to-Book | 9.51 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 13.23 | ||||
| Resistance 3 (R3) | 13.24 | 13.02 | 13.10 | ||
| Resistance 2 (R2) | 13.02 | 12.83 | 13.01 | 13.06 | |
| Resistance 1 (R1) | 12.75 | 12.71 | 12.89 | 12.74 | 13.02 |
| Pivot Point | 12.53 | 12.53 | 12.59 | 12.52 | 12.53 |
| Support 1 (S1) | 12.26 | 12.34 | 12.40 | 12.25 | 11.96 |
| Support 2 (S2) | 12.04 | 12.22 | 12.03 | 11.92 | |
| Support 3 (S3) | 11.77 | 12.04 | 11.88 | ||
| Support 4 (S4) | 11.76 |
